Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: "going the extra mile".

Antimicrobial agents and chemotherapy - 6 May 2026

Fabrizio Claudia, Valzano Felice, Giuliano Simone, Morelli Elisabetta, Serio Daniela, Buccoliero Giovanni Battista, Cervellera Maurizio, La Bella Gianfranco, Arena Fabio, Hujer Andrea M, Taracila Magdalena A, Marshall Steven H, Bonomo Robert A, Tascini Carlo

Abstract excerpt

A 65-year-old man without identifiable risk factors for multidrug-resistant pathogens was admitted with peritonitis, isolating NDM-producing Escherichia coli from a rectal swab and intraoperative samples. After surgery, ceftazidime-avibactam/aztreonam was administered. Due to poor clinical response, he was switched to imipenem-relebactam/aztreonam, resulting in a successful outcome. Whole-genome sequencing...

Topics

Join the communities discussing this publication.

Azabicyclo Compounds
beta-Lactamases
Ceftazidime
Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Drug Resistance, Multiple, Bacterial

Escherichia coli Infections

Penicillin-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41718487
DOI: 10.1128/aac.00887-25
PMCID: PMC13148025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: "going the extra mile".PMID 41718487Read ↗

Introducing the new face of CLSI M100 in 2023: An explanatory reviewSemantic proximity Read ↗

Precision Medicine and Mysteries in Clinical Microbiology: Rationalizing Epidemiology, Genotype, and Phenotype To Guide Therapeutics.Semantic proximity Read ↗

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam ResistanceSemantic proximity Read ↗

The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?Semantic proximity Read ↗

Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baselineSemantic proximity Read ↗

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumanniiSemantic proximity Read ↗

Treatment options for New Delhi metallo-beta-lactamase-harboring enterobacteriaceae.Semantic proximity Read ↗

Expanding antimicrobial chemical space by engineering drug safetySemantic proximity Read ↗

[A temperature-inducible Targetron system for efficient gene inactivation in Escherichia coli].Semantic proximity Read ↗

Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.